When the Deal Closes, the Data Work Begins: How Snowflake Accelerates M&A and Divestitures in Life Sciences
Snowflake, Friday, August 14th, 2026
Snowflake examines why life sciences M&A data integration is uniquely constrained by GxP validation and privacy law.
Snowflake examines why mergers, acquisitions and divestitures are uniquely complicated in life sciences, where clinical trial results, regulatory submissions and quality records form the backbone of every product.
Acquiring a biotech means inheriting years of research, validated systems and compliance obligations, while a spin-off requires separating data commingled for decades under strict legal timelines.
Obstacles include regulatory continuity, since clinical trial records must stay intact during transitions and FDA inspections do not pause for integration, plus GxP-validated systems that cannot be migrated without change control. Patient data obligations under HIPAA and GDPR add further constraints. Snowflake positions its platform as a way to compress those integration timelines.